NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?